Digest Network Come funziona
Network
/
Società
Ar
Non verificato

Arrowhead Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

70 comunicati stampa

Guarda tutti i comunicati
20/01/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Mercato azionario
Titoli e azioni
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Salute
Farmaceutica
Finanza
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Industria
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Industria
Salute
Biotecnologia
Farmaceutica
Medicina - Varie
Sanità
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/12/2025
Eventi
Fiere
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
15/12/2025
Mercato azionario
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Biologia
Sanità
Farmaceutica
Salute
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/12/2025
Industria
Igiene alimentare
Salute
Scienza
Farmaceutica
Biotecnologia
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0